Gastroesophageal reflux disease, a chronic digestive disorder, is a risk factor for esophageal cancer. Considered the second most lethal cancer in the U.S., esophageal cancer is more common in men than women, with over 80 percent of patients dying within five years of diagnosis. Early esophageal precancer can be monitored for progression to late esophageal precancer which can be cured with endoscopic esophageal ablation, reliably halting progression to cancer.
The American Cancer Society estimates that about 22,070 new esophageal cancer cases will be diagnosed and there will be roughly 16,250 deaths from esophageal cancer in 2025.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com